8-K: CervoMed Reports Strong Phase 2b DLB Trial Data

CervoMed Inc. announced positive 32-week data from its Phase 2b RewinD-LB trial for neflamapimod in Dementia with Lewy Bodies, showing significant reduction in clinical worsening and a key biomarker, alongside increased net loss for Q2 2025.

Summary

• CervoMed reported financial results and corporate updates for the second quarter ended June 30, 2025.
• 32-week data from the Phase 2b RewinD-LB trial Extension phase showed neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to the control arm over 32 weeks.
• Patients treated with neflamapimod demonstrated a 54% risk reduction in clinically significant worsening (CDR-SB) compared to control at Week 32 (p=0.0037).
• This risk reduction improved to 64% (p=0.0001) among patients with minimal evidence of Alzheimer's disease co-pathology (ptau181 < 2.2 pg/mL at screening).
• At Week 32 of the Extension phase, neflamapimod-treated patients showed a statistically significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP), a neurodegenerative biomarker, with a mean change of -18.4 ± 4.0 pg/mL in all participants (N=107) and -21.2 ± 4.4 pg/mL in participants with screening plasma ptau181 below 2.2 pg/mL (N=91).
• In contrast, placebo-recipients in the initial double-blind phase had a mean increase in GFAP of +1.1 ± 3.0 pg/mL.
• The initial double-blind phase of the RewinD-LB trial did not effectively evaluate neflamapimod due to a batch of capsules that did not achieve expected plasma drug concentrations; the Extension phase utilized a newer batch that did.
• Cash, cash equivalents, and marketable securities were approximately $33.5 million as of June 30, 2025, down from $38.9 million as of December 31, 2024.
• Net loss for the three months ended June 30, 2025, was approximately $6.3 million, compared to a net loss of approximately $2.3 million for the same period in 2024.
• Research and Development (R&D) expenses increased to approximately $5.1 million in Q2 2025 from $3.8 million in Q2 2024.
• General and Administrative (G&A) expenses increased to approximately $3.3 million in Q2 2025 from $2.5 million in Q2 2024.
• Grant revenue decreased to approximately $1.8 million in Q2 2025 from $3.3 million in Q2 2024 due to the completion of the initial RewinD-LB trial phase.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to compelling clinical trial results for neflamapimod in DLB, showing significant efficacy and biomarker improvements, which de-risks the program substantially. The expansion into new indications and a new executive hire also contribute positively. However, the increased net loss and the explicit need for future funding for the Phase 3 trial introduce a degree of financial uncertainty, preventing a perfect score.

Positives

• Neflamapimod demonstrated a substantial 54% risk reduction in clinically significant worsening in DLB patients, improving to 64% in those with minimal AD co-pathology.
• Statistically significant reduction in GFAP, a key neurodegenerative biomarker, supports neflamapimod's impact on the underlying disease process.
• Successful completion and positive data from the 32-week Extension phase of the Phase 2b RewinD-LB trial provide strong proof-of-concept for slowing clinical progression in DLB.
• The company plans to engage with the FDA in Q4 2025 to align on Phase 3 trial design, indicating progress towards pivotal studies.
• Neflamapimod received Orphan Drug designation for the treatment of Frontotemporal Dementia (FTD) in November 2024, potentially accelerating development and market access for this indication.
• Initiation of new Phase 2a trials for neflamapimod in acute stroke recovery and primary progressive aphasia (PPA) expands the drug's potential indications.

Negatives

• Net loss significantly increased to approximately $6.3 million for Q2 2025, compared to $2.3 million for Q2 2024.
• Cash, cash equivalents, and marketable securities decreased to $33.5 million as of June 30, 2025, from $38.9 million at year-end 2024, indicating a notable cash burn.
• Research and Development (R&D) expenses increased by $1.3 million, primarily due to increased CMC activities, non-clinical studies, headcount, and outsourced CRO costs.
• General and Administrative (G&A) expenses increased by $0.8 million, mainly due to headcount costs and outsourced services.
• Grant revenue decreased due to the completion of the initial, double-blind phase of the RewinD-LB Trial, impacting funding for ongoing operations.
• The initial double-blind phase of the RewinD-LB trial was compromised by a batch of capsules that did not achieve targeted plasma drug concentrations, necessitating reliance on the Extension phase for efficacy evaluation.

Risks

• The company's available cash resources and the availability of additional funds on acceptable terms are critical for future operations, especially for initiating the planned Phase 3 trial.
• There is no guarantee that initial clinical results observed with neflamapimod in the RewinD-LB trial will be replicated in later, larger trials.
• The likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback from the FDA are uncertain.
• The ability to implement business plans, forecasts, and other expectations in the future is subject to various uncertainties.
• General economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts could adversely affect the company's operations and financial performance.

Future Outlook

CervoMed plans to meet with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 to align on the design of its planned Phase 3 trial for neflamapimod in Dementia with Lewy Bodies (DLB), which it aims to initiate in mid-2026, subject to available funding. Initial safety, biomarker, and pharmacokinetic data from an ongoing trial evaluating a twice-daily regimen (80mg BID) of neflamapimod in mild-to-moderate DLB patients are expected in the fourth quarter of 2025. The company also initiated Phase 2a trials for neflamapimod in patients recovering from acute stroke and in patients with the nonfluent/agrammatic variant of primary progressive aphasia (PPA) in mid-2025.

Management Comments

• "With the reporting of both 16and 32-week Extension phase data from the Phase 2b RewinD-LB trial, we have solidified the evidence for slowing clinical progression in DLB associated with neflamapimod treatment."
• "This proof-of-concept, combined with the notable reductions seen in plasma levels of GFAP, an important blood-based biomarker of the underlying neurodegenerative process in DLB, provide us with valuable results and a deeper understanding that further increases our confidence in Phase 3 success and neflamapimod’s potential to make a meaningful difference for patients if approved."
• "We are actively preparing for discussions with the FDA, which we expect to take place in the fourth quarter of 2025, to align on the design of our planned Phase 3 trial."

Industry Context

The positive clinical data for neflamapimod in Dementia with Lewy Bodies (DLB) is significant within the neurodegenerative disorder landscape, where effective treatments are scarce. The focus on reducing clinically significant worsening and impacting a key neurodegenerative biomarker (GFAP) aligns with industry efforts to develop disease-modifying therapies. The exclusion of patients with significant Alzheimer's disease co-pathology (ptau181 < 2.2 pg/mL) highlights a growing trend in clinical trials to target more specific patient populations for better treatment response, acknowledging the heterogeneity of neurodegenerative diseases. The expansion into acute stroke and Frontotemporal Dementia (FTD) also positions CervoMed to address broader neurological needs, leveraging neflamapimod's mechanism of inhibiting p38 mitogen-activated protein kinase alpha, which is implicated in synaptic dysfunction across various conditions.

Management Changes

Stakeholder Impact

• **Shareholders**: Positive clinical data could lead to increased investor confidence and potential share price appreciation, but the need for future capital raises may lead to dilution.
• **Patients**: The positive Phase 2b results offer significant hope for a new treatment option for Dementia with Lewy Bodies, a debilitating neurodegenerative disorder with limited therapies.
• **Employees**: Increased headcount costs and the hiring of a new EVP suggest company growth and stability for existing employees, as well as new opportunities.
• **Creditors**: The company's cash position and burn rate will be closely monitored, especially given the explicit need for future funding for Phase 3 trials.

Next Steps

• Meet with the FDA in Q4 2025 to align on the design of the planned Phase 3 trial for neflamapimod in DLB.
• Initiate the Phase 3 trial in mid-2026, subject to available funding.
• Expect initial safety, biomarker, and pharmacokinetic data from the 80mg BID neflamapimod trial in mild-to-moderate DLB in Q4 2025.
• Continue Phase 2a trials for neflamapimod in patients recovering from acute stroke and in patients with the nonfluent/agrammatic variant of primary progressive aphasia (PPA).

Key Dates

Recommendation

The strong positive clinical data from the Phase 2b RewinD-LB trial, demonstrating significant reduction in clinical worsening and a key biomarker, provides compelling evidence for neflamapimod's therapeutic potential in DLB. This de-risks the drug candidate significantly and positions CervoMed for a pivotal Phase 3 program. While the company reported an increased net loss and a need for future funding, which introduces financial risk, the clinical efficacy in a high-unmet-need indication like DLB is a powerful driver for long-term value creation. A seasoned investor would likely view this as a strategic entry point, acknowledging the potential for future dilution but prioritizing the strong scientific validation and market opportunity.

Keywords

CervoMed, CRVO, neflamapimod, Dementia with Lewy Bodies, DLB, neurodegenerative disorders, clinical trial, Phase 2b, Phase 3, FDA, biomarker, GFAP, Alzheimer's disease, Orphan Drug, Frontotemporal Dementia, FTD, stroke, biotechnology, pharmaceuticals, neurology